
Development and provision of biotherapies for rare and serious diseases, including bleeding disorders, immunodeficiencies, and neurological disorders.
+160,000
Total organizations analyzedAnalysis by axis
Access the detailed report with all sector benchmarks, in-depth competitive analysis and actionable recommendations.
Methodology: Score calculated according to 6 CSR themes (Carbon, Biodiversity, Circular Economy, Sustainable Investments, Governance, Social Impact)
Sources: Public data, CSR reports, documented initiatives, official databases
Last update: December 2025
This analysis is not yet available in English. Please see the French version.
A
The organization is among the top 5% of organizations with the most committed CSR communication, among comparable organizations.
Leading organizations
Takeda
B
Development and commercialization of innovative medicines in various therapeutic areas, including gastrointestinal diseases, rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccines.
Orphan Europe
B
Development and commercialization of drugs for rare diseases.
Genethon
B
Research and development of gene therapy medicines for the treatment of rare diseases.
Initiatives identified among leaders
Développement de programmes de responsabilité sociale
“Takeda développe des programmes de responsabilité ...” - TakedaAméliorer l'accès aux soins
“Orphan Europe améliore l'accès aux soins en dévelo...” - Orphan EuropeMise en place d'un processus de divulgation de vulnérabilités
“Takeda met en place un processus de divulgation de...” - Takeda64% of similar organizations communicate on CSR issues
+3117 initiatives collected from 100 similar organizations
Is your score incomplete? Update your CSR information and improve your positioning.
Claim this page
Updated data
Personalized recommendations
Access complete data, competitive analyses and actionable recommendations for your clients.
Comprehensive sector benchmarks
Competitive data
Ready-to-use reports